Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  Breaking News: FDA Approves Triumeq, New Once-Daily Combination Pill
   
Ask the Experts About

Managing Side Effects of HIV TreatmentManaging Side Effects of HIV Treatment
           
Rollover images to visit our other forums!
Recent AnswersAsk a Question
  
  • Email Email
  • Glossary Glossary


Resistance to Atripla
Feb 14, 2009

My partner is currently on Atripla which they say he is becoming resistant - he has been diagnosed with HIV and has lived with it for over 24 years. His current CD4 count is 70 and Viral load is 63000... Following a new test called Trofile ? they are considering a drug from the CCR5 Antagonnist class "Maraviroc" - which we believe is relatively new ... what is know about it's effectiveness ..

Response from Dr. Henry

If the Trofile new generation assay shows R5 virus than miraviroc would be expected to contribute to control of the virus in a new regimen which often would include several other newer drugs (such as raltegravir, darunavir, etravirine) based on treatment history and resistance testings. Miraviroc has been a generally effective and well tolerated drug when used properly. KH



Previous
diastasis recti?
Next
rash on face

  
  • Email Email
  • Glossary Glossary

 Get Email Notifications When This Forum Updates or Subscribe With RSS


 
Advertisement



Q&A TERMS OF USE

This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.

Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.

Review our complete terms of use and copyright notice.

Powered by ExpertViewpoint

Advertisement